Comparative Pharmacology
Head-to-head clinical analysis: TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE versus XERAVA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE versus XERAVA.
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE vs XERAVA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Trimethoprim inhibits bacterial dihydrofolate reductase, blocking tetrahydrofolate synthesis and thereby inhibiting thymidine synthesis. Polymyxin B disrupts bacterial cell membrane integrity by binding to lipopolysaccharides in Gram-negative bacteria.
Eravacycline is a tetracycline-class antibacterial that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from attaching to the A-site. It exhibits activity against a broad range of Gram-positive, Gram-negative, and anaerobic bacteria, including many tetracycline-resistant strains due to modifications circumventing common resistance mechanisms.
One drop in each affected eye every 2 to 4 hours for 7 to 10 days.
200 mg intravenously over 60 minutes every 12 hours
None Documented
None Documented
Trimethoprim: 8-10 hours (normal renal function); Polymyxin B: 6 hours (prolonged in renal impairment).
Terminal elimination half-life is approximately 42 hours (range 30-60 hours) in healthy subjects; prolonged in elderly patients and those with severe hepatic impairment.
Trimethoprim: renal (80-90% unchanged, 10-20% metabolites); Polymyxin B: renal (60% unchanged, 40% nonrenal).
Fecal (approximately 80-90% as unchanged drug); renal (less than 1% as unchanged drug).
Category D/X
Category C
Antibiotic
Antibiotic